Immix Biopharma reports 75% CR rate in Phase 2 NXC-201 for AL amyloidosis, BLA plan 2026

Immix Biopharma, Inc.

NXC-201 achieved 75% complete response (15/20) by independent review committee in relapsed/refractory AL amyloidosis.
MRD negativity in 4 of 5 pending patients suggests future CR rate could reach 95%.
Organ responses observed in 70% of evaluable patients; no neurotoxicity and only low-grade CRS (median 1 day).
NEXICART-2 final readout and BLA submission planned for 2026; therapy has FDA RMAT and orphan designations.
Current standard-of-care CR rate in this setting is under 10%, highlighting high unmet need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.